Kristie L. Kahl

“This is a pivotal phase 3 trial that I think is going to be practice changing to the urology community,” said Brian Shuch, MD.

Adding apalutamide to ADT with or without abiraterone acetate/prednisone significantly prolonged PSA PFS in men with biochemically relapsed prostate cancer, according to extended follow-up from the phase 3 PRESTO study.

“These results further support nivolumab as a standard of care for high-risk MIUC and MIBC after radical resection,” said Matthew Milowsky, MD.

Single-dose URO-902 appeared to be safe and effective in treating women with overactive bladder and urge urinary incontinence, according to the final analysis of a phase 2a trial.

The results may help guide the decision between a partial and radical nephrectomy in patients with stage T1b to T2 renal cell carcinoma.

The deep PSA responses with the darolutamide regimen were found to be correlated with improved overall survival and a prolonged time to PSA progression.

Irrespective of response to first-line platinum-based chemotherapy, frontline maintenance therapy with avelumab plus best supportive care (BSC), compared with BSC alone, prolonged overall and progression-free survival in patients with advanced urothelial carcinoma.

"Dose reduction for patients with small body size may alleviate skin AEs without sacrificing oncological outcomes,” said Kyo Togashi.

“So I think what we can take away from this study is that just because your patient [has a higher BMI], doesn't mean that they're a poor candidate for a partial nephrectomy,” said Lachlan Shiver.

Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.

As stereotactic ablative radiation therapy enters further into the treatment space for metastatic RCC, integration of the approach is vital for physicians to focus on, according to Raquibul Hannan, MD, PhD.

Compared with data from the KEYNOTE-057 study, the use of pembrolizumab monotherapy in the real-world setting was similar in the treatment of patients with high-risk non-muscle invasive bladder cancer.

The combination use of PSMA-targeted radionuclide therapy tailored by the individual patient and dose may show promise in the future treatment of men with metastatic castration-resistant prostate cancer.

“There is a critical unmet need for efficacious bladder-sparing therapies for patients with BCG-unresponsive bladder cancer,” said Roger Li, MD.

The combination use of cabozantinib plus nivolumab and ipilimumab reduced the risk for disease progression by 27% in patients with previously untreated advanced renal cell carcinoma.

Treatment with radiotherapy and 2 years of ADT may improve outcomes for men following radical prostatectomy, helping patients and physicians make an evidence-based choice.

Although the phase 3 CheckMate 914 trial missed its primary end point of improved DFS, the rate of treatment discontinuation may have played a role in the results, according to Robert J. Motzer, MD.

The IELT significantly increased by 3.22-fold in the Mini-patch device group, compared with the sham group (P = .0047).

“This study demonstrates the superiority of the SP in patient-reported cosmetic and pain outcomes on short- and long-term follow-up after uro-oncological surgical procedures,” the study authors concluded.

“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”

"A single dose of URO-902 24 mg or 48 mg was associated with clinically relevant improvement in efficacy and quality of life and was safe and well tolerated," says Kenneth M. Peters, MD.

Early findings from the phase 2 CORE1 trial showed that the combination of the novel oncolytic immunotherapy CG0070 and the immune checkpoint inhibitor pembrolizumab was safe and active in patients with BGG-unresponsive NMIBC.

Results shared during the 2022 AACR Annual Meeting suggested that genetic adjustment of prostate-specific antigen may reduce overdiagnosis of prostate cancer, de-escalate invasive testing, and improve the detection of aggressive disease.

TLX591-CDx (Illuccix) is a radiopharmaceutical cold kit for the preparation of gallium-68 PSMA-11 injection.

According to extended follow-up from the phase 3 Checkmate 274 trial, nivolumab continued to demonstrate improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma.

The PET agent targeting prostate specific membrane antigen (PSMA) 18F-DCFPyL effectively detected recurrent lesions in prostate cancer patients with biochemical recurrence.

Data from the phase 1b ABC Trial showed that adding avelumab to BCG induction therapy may be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Adding bone-protecting agents to the treatment of men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer helped to reduce their risk for fracture.

Tivozanib is approved by the FDA for the treatment of patients with relapsed or refractory advanced renal cell carcinoma who have received 2 or more prior systemic therapies.

Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.